A single IA injection of iPAAG was associated with sustained improvements in pain and function, with a favourable safety profile maintained through 5 years. These observational data support iPAAG as a promising long-acting, non-surgical treatment option for knee OA.
Bliddal et al. (Wed,) studied this question.